Abstract: Objective： To compare the curative effects and adverse reactions of mifepristone of different doses in treatment of adenomyosis， evaluate the recurrence of adenomyosis after drug withdrawal. Methods： 238 patients diagnosed with adenomyosis in our hospital were selected as subjects. They were randomly divided into mifepristone 40 mg·d-1 group (n=122 cases) and mifepristone 20 mg·d-1 group (n=116 cases)， and treated with mifepristone of different doses for nine months. The three-dimensional diameters of uterus were measured by ultrasound before and after treatment. The serum hemoglobin concentration and endometrial conditions were evaluated. All the cases were followed up for 9 months，recurrence of adenomyosis was observed. Results： Mifepristone of different doses (40 and 20 mg·d-1) can significantly improve the related clinical symptoms， increase the concentration of serum hemoglobin and reduce the volume of uterus， but there was no significant difference between the two groups (P>0.05). There was no significant difference in recurrence rate of adenomyosis 3，6 and 9 months after drug withdrawal between the two groups(P>0.05). The incidence of irregular hyperplasia of endometrium in 20 mg·d-1 group was significantly lower than that in 40 mg·d-1 group (P<0.05). Conclusion： Mifepristone of different doses (40 and 20 mg·d-1) can reduce the volume of uterus and improve clinical symptoms， but mifepristone of 20mg·d-1 is more safe. The recurrence rate of adenomyosis treated with mifepristone is high， but the use of mifepristone before operation is suggested.